CA2060937A1 - Anti-reactive anti-asthmatic activity of non-steroidal anti-inflammatory drugs by inhalation - Google Patents

Anti-reactive anti-asthmatic activity of non-steroidal anti-inflammatory drugs by inhalation

Info

Publication number
CA2060937A1
CA2060937A1 CA002060937A CA2060937A CA2060937A1 CA 2060937 A1 CA2060937 A1 CA 2060937A1 CA 002060937 A CA002060937 A CA 002060937A CA 2060937 A CA2060937 A CA 2060937A CA 2060937 A1 CA2060937 A1 CA 2060937A1
Authority
CA
Canada
Prior art keywords
inhalation
patients
inhaled
unw
bronchial
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002060937A
Other languages
English (en)
French (fr)
Inventor
Sebastiano Bianco
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hoechst AG
Original Assignee
Sebastiano Bianco
Hoechst Aktiengesellschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sebastiano Bianco, Hoechst Aktiengesellschaft filed Critical Sebastiano Bianco
Publication of CA2060937A1 publication Critical patent/CA2060937A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/02—Halogenated hydrocarbons
    • A61K31/025—Halogenated hydrocarbons carbocyclic
    • A61K31/03—Halogenated hydrocarbons carbocyclic aromatic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA002060937A 1991-02-09 1992-02-10 Anti-reactive anti-asthmatic activity of non-steroidal anti-inflammatory drugs by inhalation Abandoned CA2060937A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP91101818 1991-02-09
EP91101818.2 1991-02-09

Publications (1)

Publication Number Publication Date
CA2060937A1 true CA2060937A1 (en) 1992-08-10

Family

ID=8206393

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002060937A Abandoned CA2060937A1 (en) 1991-02-09 1992-02-10 Anti-reactive anti-asthmatic activity of non-steroidal anti-inflammatory drugs by inhalation

Country Status (16)

Country Link
US (1) US6051566A (he)
JP (1) JPH0648958A (he)
KR (1) KR920016086A (he)
AT (1) ATE179605T1 (he)
AU (1) AU662509B2 (he)
BR (1) BR9200429A (he)
CA (1) CA2060937A1 (he)
CZ (1) CZ281970B6 (he)
DE (1) DE69229070T2 (he)
HU (1) HUT60917A (he)
IE (1) IE920427A1 (he)
IL (1) IL100896A (he)
MX (1) MX9200571A (he)
NO (1) NO179893C (he)
NZ (1) NZ241542A (he)
ZA (1) ZA92890B (he)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060165606A1 (en) 1997-09-29 2006-07-27 Nektar Therapeutics Pulmonary delivery particles comprising water insoluble or crystalline active agents
US6946117B1 (en) * 1997-09-29 2005-09-20 Nektar Therapeutics Stabilized preparations for use in nebulizers
US7871598B1 (en) 2000-05-10 2011-01-18 Novartis Ag Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use
US8404217B2 (en) 2000-05-10 2013-03-26 Novartis Ag Formulation for pulmonary administration of antifungal agents, and associated methods of manufacture and use
TWI290473B (en) 2000-05-10 2007-12-01 Alliance Pharma Phospholipid-based powders for drug delivery
US6613308B2 (en) * 2000-09-19 2003-09-02 Advanced Inhalation Research, Inc. Pulmonary delivery in treating disorders of the central nervous system
US7256184B2 (en) * 2000-10-16 2007-08-14 Rodriguez Victorio C Treatment of aging disorders in humans
US7766013B2 (en) 2001-06-05 2010-08-03 Alexza Pharmaceuticals, Inc. Aerosol generating method and device
EP1392262A1 (en) * 2001-05-24 2004-03-03 Alexza Molecular Delivery Corporation Delivery of drug esters through an inhalation route
US7458374B2 (en) 2002-05-13 2008-12-02 Alexza Pharmaceuticals, Inc. Method and apparatus for vaporizing a compound
WO2002094246A2 (en) * 2001-05-24 2002-11-28 Alexza Molecular Delivery Corporation Delivery of nonsteroidal antiinflammatory drugs through an inhalation route
US6759029B2 (en) * 2001-05-24 2004-07-06 Alexza Molecular Delivery Corporation Delivery of rizatriptan and zolmitriptan through an inhalation route
US6805853B2 (en) * 2001-11-09 2004-10-19 Alexza Molecular Delivery Corporation Delivery of diazepam through an inhalation route
US7645442B2 (en) 2001-05-24 2010-01-12 Alexza Pharmaceuticals, Inc. Rapid-heating drug delivery article and method of use
US20070122353A1 (en) 2001-05-24 2007-05-31 Hale Ron L Drug condensation aerosols and kits
US7498019B2 (en) 2001-05-24 2009-03-03 Alexza Pharmaceuticals, Inc. Delivery of compounds for the treatment of headache through an inhalation route
ATE415155T1 (de) * 2001-05-24 2008-12-15 Alexza Pharmaceuticals Inc Verabreichung von alprazolam, estazolam, midazolam oder triazolam durch inhalation
AU2002352726A1 (en) 2001-11-15 2003-06-10 Galileo Laboratories, Inc. Formulations and methods for treatment or amelioration of inflammatory conditions
WO2003057188A1 (en) * 2001-11-21 2003-07-17 Alexza Molecular Delivery Corporation Delivery of caffeine through an inhalation route
PT1458360E (pt) 2001-12-19 2011-07-13 Novartis Ag Derivados de indole como agonistas do recetor s1p1
US8003080B2 (en) 2002-05-13 2011-08-23 Alexza Pharmaceuticals, Inc. Delivery of drug amines through an inhalation route
US20060193788A1 (en) * 2002-11-26 2006-08-31 Hale Ron L Acute treatment of headache with phenothiazine antipsychotics
US20040105818A1 (en) 2002-11-26 2004-06-03 Alexza Molecular Delivery Corporation Diuretic aerosols and methods of making and using them
AU2003294470B2 (en) * 2002-11-26 2009-09-17 Alexza Pharmaceuticals, Inc. Use of loxapine and amoxapine for the manufacture of a medicament for the treatment of pain
US7550133B2 (en) * 2002-11-26 2009-06-23 Alexza Pharmaceuticals, Inc. Respiratory drug condensation aerosols and methods of making and using them
WO2004047841A1 (en) * 2002-11-26 2004-06-10 Alexza Molecular Delivery Corporation Treatment of headache with antipsychotics delivered by inhalation
US7913688B2 (en) 2002-11-27 2011-03-29 Alexza Pharmaceuticals, Inc. Inhalation device for producing a drug aerosol
US20040234699A1 (en) 2003-05-21 2004-11-25 Alexza Molecular Delivery Corporation Methods of controlling uniformity of substrate temperature and self-contained heating unit and drug-supply unit employing same
US7540286B2 (en) 2004-06-03 2009-06-02 Alexza Pharmaceuticals, Inc. Multiple dose condensation aerosol devices and methods of forming condensation aerosols
US8455437B2 (en) * 2005-02-04 2013-06-04 The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Method to predict and prevent oxygen-induced inflammatory tissue injury
ITMI20050417A1 (it) * 2005-03-15 2006-09-16 Medestea Res & Production S R L Uso di farmaci anti-infiammatori non steroidei per via inalatoria nella terapia della bronchite acuta e cronica
US20070203104A1 (en) * 2006-02-09 2007-08-30 Chaudhry Saeed M Pharmaceutical Formulations
JP5094197B2 (ja) * 2006-04-27 2012-12-12 第一三共ヘルスケア株式会社 杯細胞過形成を抑制するための抗ヒスタミン剤含有医薬組成物
US20080216828A1 (en) 2007-03-09 2008-09-11 Alexza Pharmaceuticals, Inc. Heating unit for use in a drug delivery device
DE102008004386A1 (de) * 2008-01-14 2009-07-23 Activaero Gmbh Verwendung eines Acetylsalicylsäuresalzes zur Behandlung viraler Infektionen
CA2722668A1 (en) * 2008-04-29 2009-11-05 Wyeth Llc Methods for treating inflammation
KR101704815B1 (ko) * 2009-08-21 2017-02-09 포항공과대학교 산학협력단 Ｉｌ－１７ 매개 염증질환의 치료를 위한 조합 제제 및 이를 이용한 치료 방법
US20130281405A1 (en) * 2012-04-02 2013-10-24 Lenard M. Lichtenberger Use of pc-nsaids to treat and/or prevent pulmonary inflammation
US9757395B2 (en) 2012-12-20 2017-09-12 Otitopic Inc. Dry powder inhaler and methods of use
EP2991634A1 (en) * 2013-04-30 2016-03-09 Otitopic Inc. Dry powder formulations and methods of use
TWI586383B (zh) * 2014-04-18 2017-06-11 林信湧 一種用於治療關節炎之吸入式醫藥組成物及其備製方法
WO2016040570A2 (en) 2014-09-12 2016-03-17 Children's Medical Center Corporation Dietary emulsion formulations and methods for using the same
US11723864B2 (en) * 2015-05-29 2023-08-15 The Texas A&M University System Antimicrobial and anti-inflammatory compositions

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5244899A (en) * 1985-02-04 1993-09-14 G. D. Searle And Co. Azabicycloalkyl and azatricycloalkyl amides used to treat inflammation, allergy, asthma and skin disorders
US4885287A (en) * 1988-08-09 1989-12-05 University Of Kentucky Research Foundation Novel method of administering aspirin and dosage forms containing same

Also Published As

Publication number Publication date
AU662509B2 (en) 1995-09-07
NO179893B (no) 1996-09-30
NO920504D0 (no) 1992-02-07
CZ281970B6 (cs) 1997-04-16
IL100896A (he) 1998-02-22
AU1077292A (en) 1992-08-13
IE920427A1 (en) 1992-08-12
NO920504L (no) 1992-08-10
ZA92890B (en) 1992-12-30
NZ241542A (en) 1996-05-28
BR9200429A (pt) 1992-10-13
MX9200571A (es) 1992-12-01
US6051566A (en) 2000-04-18
DE69229070D1 (de) 1999-06-10
JPH0648958A (ja) 1994-02-22
ATE179605T1 (de) 1999-05-15
CS35292A3 (en) 1992-08-12
KR920016086A (ko) 1992-09-24
HU9200389D0 (en) 1992-04-28
HUT60917A (en) 1992-11-30
NO179893C (no) 1997-01-08
IL100896A0 (en) 1992-11-15
DE69229070T2 (de) 1999-11-18

Similar Documents

Publication Publication Date Title
US6051566A (en) Anti-reactive anti-asthmatic activity of non-steroidal anti-inflammatory drugs by inhalation
AU2005210083B2 (en) Novel combination of anticholinergic and beta mimetics for the treatment of respiratory diseases
ES2309503T3 (es) Medicamento que comprende un agonista beta 2 de larga duracion, muy potente, en combinacion con otros ingredientes activos.
US5750559A (en) Potentiation of the antireactive-antiasthmatic effect of inhaled loop diuretics by inhaled non-steroidal anti-inflammatory drugs
Nuhoğlu et al. Efficacy of aminophylline in the treatment of acute asthma exacerbation in children
EP0499143B1 (en) Anti-reactive anti-asthmatic activity of acetylsalicylic acid by inhalation
JPH037223A (ja) 吸入用喘息治療剤
Bleecker et al. Acute bronchodilating effects of ipratropium bromide and theophylline in chronic obstructive pulmonary disease
Rodrigo et al. High-dose MDI salbutamol treatment of asthma in the ED
Rasmussen et al. Reduced nonspecific bronchial reactivity and decreased airway response to antigen challenge in atopic asthmatic patients treated with the inhaled leukotriene D4 antagonist, L‐648,051
Hockley et al. A comparison of three high doses of ipratropium bromide in chronic asthma
NZ260290A (en) Use of a non-steroidal anti-inflammatory drug in the preparation of anti-asthmatic inhalant compositions
Sivan et al. A double-blind, randomized study of sodium cromoglycate versus placebo in patients with cystic fibrosis and bronchial hyperreactivity
Magnussen et al. Duration of the effect of a single dose of azelastine on histamine-induced bronchoconstriction
Albazzaz et al. Dose duration of nebulized nedocromil sodium in exercise-induced asthma
Freeman et al. The effects of ipratropium bromide and fenoterol nebulizer solutions in children with asthma
Godin et al. Acute bronchoconstriction caused by Beclovent and not Vanceril
KR20050094810A (ko) 로플루미래스트와 ｒ,ｒ-포르모테롤을 포함하는 상승작용성조합물
Selroos et al. Formoterol Turbuhaler® 4.5 μg (Delivered Dose) has a Rapid Onset and 12-h Duration of Bronchodilation
Haahtela et al. Histamine-induced bronchoconstriction is equally relieved by Easyhaler® and Diskhaler® salbutamol powder inhalers
Taitinen et al. Combination of oxitropium bromide and salbutamol in the treatment of asthma with pressurized aerosols
Sestini et al. Protective Effect of Furosemide, Administered Using a Pressurized Metered Dose Inhaler and a Spacer Device, on the Bronchial Obstructive Response to Ultrasonically Nebulized Distilled Water
Abraham Effect of nedocromil sodium on antigen-induced airway responses in allergic sheep
Rühle et al. Effects of a combined treatment theophylline and tulobuterol on nocturnal chronic asthma
Hedrick et al. Cardiac Safety of Ventolin® HFA in Children< 48 Months Old

Legal Events

Date Code Title Description
FZDE Discontinued